Norbert Bischofberger - Gilead Sciences Insider

Gilead Sciences Inc -- USA Stock  

USD 79.74  0.23  0.29%

Chief Scientific Officer and Executive VP of RandD

Dr. Norbert W. Bischofberger, Ph.D., is no longer Executive Vice President Research and Development, Chief Scientific Officer of Gilead Sciences Inc effective April 30 2018
Age: 60  EVP Since 2007  Ph.D    
Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.?s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside?s lab at Harvard University in Cambridge, Massachusetts.

Norbert Bischofberger Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 14.15 % which means that it generated profit of $14.15 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.3 % meaning that it created $23.3 on every $100 dollars invested by stockholders.
The company currently holds 33.54 B in liabilities with Debt to Equity (D/E) ratio of 163.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences Inc has Current Ratio of 2.68 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

EVP Since

Giovanni MagniBio Rad Laboratories Inc
Brian BlaserAbbott Laboratories
Thomas FreymanAbbott Laboratories
Stuart ArbuckleVertex Pharmaceuticals Incorpor
John CapekAbbott Laboratories
Hubert AllenAbbott Laboratories
Richard AshleyAbbott Laboratories
Susan HallEndo International plc

Entity Summary

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on NASDAQ. It employs 10000 people.Gilead Sciences Inc (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Gilead Sciences Inc to your portfolio

Top Management

Gilead Sciences Inc Leadership Team
Kathleen Watson, President
John McHutchison, President
Andrew Cheng, President
John Martin, Chairman, MBA
Gayle Wilson, Director
Jacqueline Barton, Director, Ph.D
Brett Pletcher, EVP
William Lee, President
John Madigan, Director
Martin Silverstein, President, MBA
Kevin Lofton, Director
Paul Carter, President
Gregg Alton, EVP
Carla Hills, Director, MBA
John Cogan, Director
John Milligan, COO, Ph.D
Nicholas Moore, Director
James Meyers, President
Kelly Kramer, Director
Robin Washington, CFO, MBA
Norbert Bischofberger, EVP, Ph.D
Per WoldOlsen, Director
Taiyin Yang, President, Ph.D
Kevin Young, COO
Etienne Davignon, Director
Richard Whitley, Director

Stock Performance

Gilead Sciences Performance Indicators